Letrozole

Letrozole, letrozole, 112809-51-5, Femara, Letrozol, CGS 20267, CGS-20267, Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-, 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile, 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, DTXSID4023202, CGS20267, NSC-759652, 7LKK855W8I, 4-[(4-CYANOPHENYL)(1H-1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE, CHEBI:6413, DTXCID503202, NSC719345, KISQALI FEMARA CO-PACK COMPONENT LETROZOLE, letrozolum, 4-((4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl)benzonitrile, 4-((4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl)benzonitrile, Letrozole Tablets, 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile), RefChem:55460, L02BG04, 4,4'-(1H-1,2,4triazol-1-ylmethylene)dibenzonitrile, 675-034-8, 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile, C17H11N5, 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile, 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole, CHEMBL1444, MFCD00866241, NCGC00016973-01, Letoval, CAS-112809-51-5, SMR000466343, Femara (TN), LETRAZOLE, HSDB 7461, SR-01000759382, 4,4'-[(1H-1,2,4-Triazol-1-yl)methylene]dibenzonitrile, Letrozole (JAN/USP/INN), UNII-7LKK855W8I, 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile, CCRIS 8822, Letrozole?, Letrozole CRS, FEM-345, Femara, Letrozole, Letrozole [USAN:USP:INN:BAN], Letrozole (Standard), 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile, LETROZOLE [INN], LETROZOLE [JAN], LETROZOLE [MI], LETROZOLE [HSDB], LETROZOLE [USAN], Prestwick0_001025, Prestwick1_001025, Prestwick2_001025, Prestwick3_001025, Femara (TN) (Novartis), LETROZOLE [MART.], LETROZOLE [USP-RS], LETROZOLE [WHO-DD], SCHEMBL4331, 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole, BIDD:PXR0130, BSPBio_001209, MLS000759455, MLS001424038, MLS002584991, MLS006010040, BIDD:GT0015, Letrozole - Bio-X trade mark, SPBio_003070, BPBio1_001331, GTPL5209, orb1308084, LETROZOLE [EP IMPURITY], LETROZOLE [ORANGE BOOK], LETROZOLE [EP MONOGRAPH], Letrozole, >=98% (HPLC), BDBM13061, EX-A965, LETROZOLE [USP MONOGRAPH], GLXC-05072, HMS1571M11, HMS2051E08, HMS2089L22, HMS2098M11, HMS2233C23, HMS3369E11, HMS3393E08, HMS3651K05, HMS3715M11, HMS5079O19, Pharmakon1600-01502354, IVB71296, MSK10362, Tox21_110719, Tox21_303572, EBC-04408, HY-14248R, NSC759652, s1235, STL451047, AKOS005145822, AB07525, AC-1193, CCG-100849, CS-1776, DB01006, FL24873, KS-1269, NC00099, NSC 759652, NSC-719345, NCGC00016973-02, NCGC00016973-03, NCGC00016973-06, NCGC00257460-01, BL164620, HY-14248, 1-Bis(4-cyanophenyl)methyl-1,2,4-triazole, 4,2,4-Triazol-1-ylmethylene)dibenzonitrile, AB00514009, L0248, NS00000663, SW197294-4, C08163, D00964, EN300-264820, AB00514009-05, AB00514009-07, AB00514009-08, AB00514009-09, AB00514009_10, AB00514009_11, F036495, Q194974, W-60273, 4,4'-(1,2,4-Triazol-1-ylmethylene)dibenzonitrile, Q-201291, SR-01000759382-4, SR-01000759382-5, BRD-K88789588-001-03-2, BRD-K88789588-001-14-9, 4,4 -(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile, F2173-0288, Z1741968261, 4,4'-((1H-1,2,4-Triazol-1-yl)-methylene)dibenzonitrile, 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bis[benzonitrile], Letrozole, European Pharmacopoeia (EP) Reference Standard, Letrozole, United States Pharmacopeia (USP) Reference Standard, TRANS-1-(4-BUTYL-CYCLOHEXYL)-4-ETHOXY-2,3-DIFLUORO-BENZENE, 4-[1-(4-CYANOPHENYL)-1-(1,2,4-TRIAZOL-1-YL)METHYL]BENZONITRILE, Letrozole, Pharmaceutical Secondary Standard, Certified Reference Material, CGS 20267, Femara, Lerozole, Letrazole, 4,4'-((1H-1,2,4-triazol-1-yl)methylene)dibenzonitrile